Epigenetic considerations and the clinical reevaluation of the overlap syndrome between primary biliary cirrhosis and autoimmune hepatitis

Qixia Wang, Carlo Selmi, Xinmin Zhou, Dekai Qiu, Zenshan Li, Qi Miao, Xiaoyu Chen, Jianhong Wang, Edward L. Krawitt, M. Eric Gershwin, Ying Han, Xiong Ma

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

Epigenetic changes are of crucial importance in the etiopathogenesis of autoimmune liver diseases. Among these, there is limited agreement on the definitions and treatment of primary biliary cirrhosis (PBC) and autoimmune hepatitis (AIH) overlap syndromes, we evaluated a large series of consecutive patients with PBC (n = 565) and AIH (n = 196) to identify a group of patients with corticosteroid-responsive PBC-AIH overlap syndrome. Within this series, a total of 490 patients were biopsied based upon staging or diagnostic needs. Review of the biopsies in conjunction with the International AIH Group criteria identified 80 patients with suspected overlap syndrome and 52 patients agreed to participate in the study and were prospectively treated with corticosteroids. Of these, 40/52 (77%) achieved a complete biochemical response (i.e. normal ALT, AST, and IgG) within 12 months of treatment. A survey of pre-treatment characteristics of the 40 responders revealed more severe interface hepatitis. Serum IgG levels ≥1.3x the upper limit of normal had 60% sensitivity and 97% specificity rates for steroid-responsiveness while the use of a higher threshold (≥2.0x) reduced sensitivity to 10%. When the Paris criteria for PBC-AIH were applied to the steroid-responsive patients, 29/40 (73%) cases fulfilled at least two of the three Paris criteria. Applying the recently designed simplified IAIHG scoring system, 35/40 (88%) had a "definite" diagnosis of AIH. This study supports the hypothesis that a complete response to corticosteroids may denote a variant of a PBC-AIH overlap syndrome which could be identified prior to treatment by modified Paris criteria in concert with the simplified IAIHG scoring system.

Original languageEnglish (US)
Pages (from-to)140-145
Number of pages6
JournalJournal of Autoimmunity
Volume41
DOIs
StatePublished - Mar 2013

Fingerprint

Autoimmune Hepatitis
Biliary Liver Cirrhosis
Epigenomics
Paris
Adrenal Cortex Hormones
Immunoglobulin G
Steroids
Therapeutics
Hepatitis
Autoimmune Diseases
Liver Diseases
Biopsy
Sensitivity and Specificity
Serum

Keywords

  • AIH
  • Autoimmune cholangitis
  • Autoimmune hepatitis
  • Corticosteroid therapy
  • IAIHG
  • Overlap syndromes
  • PBC

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

Epigenetic considerations and the clinical reevaluation of the overlap syndrome between primary biliary cirrhosis and autoimmune hepatitis. / Wang, Qixia; Selmi, Carlo; Zhou, Xinmin; Qiu, Dekai; Li, Zenshan; Miao, Qi; Chen, Xiaoyu; Wang, Jianhong; Krawitt, Edward L.; Gershwin, M. Eric; Han, Ying; Ma, Xiong.

In: Journal of Autoimmunity, Vol. 41, 03.2013, p. 140-145.

Research output: Contribution to journalArticle

Wang, Qixia ; Selmi, Carlo ; Zhou, Xinmin ; Qiu, Dekai ; Li, Zenshan ; Miao, Qi ; Chen, Xiaoyu ; Wang, Jianhong ; Krawitt, Edward L. ; Gershwin, M. Eric ; Han, Ying ; Ma, Xiong. / Epigenetic considerations and the clinical reevaluation of the overlap syndrome between primary biliary cirrhosis and autoimmune hepatitis. In: Journal of Autoimmunity. 2013 ; Vol. 41. pp. 140-145.
@article{6b36e8901f1446778ac9095dd51f28a0,
title = "Epigenetic considerations and the clinical reevaluation of the overlap syndrome between primary biliary cirrhosis and autoimmune hepatitis",
abstract = "Epigenetic changes are of crucial importance in the etiopathogenesis of autoimmune liver diseases. Among these, there is limited agreement on the definitions and treatment of primary biliary cirrhosis (PBC) and autoimmune hepatitis (AIH) overlap syndromes, we evaluated a large series of consecutive patients with PBC (n = 565) and AIH (n = 196) to identify a group of patients with corticosteroid-responsive PBC-AIH overlap syndrome. Within this series, a total of 490 patients were biopsied based upon staging or diagnostic needs. Review of the biopsies in conjunction with the International AIH Group criteria identified 80 patients with suspected overlap syndrome and 52 patients agreed to participate in the study and were prospectively treated with corticosteroids. Of these, 40/52 (77{\%}) achieved a complete biochemical response (i.e. normal ALT, AST, and IgG) within 12 months of treatment. A survey of pre-treatment characteristics of the 40 responders revealed more severe interface hepatitis. Serum IgG levels ≥1.3x the upper limit of normal had 60{\%} sensitivity and 97{\%} specificity rates for steroid-responsiveness while the use of a higher threshold (≥2.0x) reduced sensitivity to 10{\%}. When the Paris criteria for PBC-AIH were applied to the steroid-responsive patients, 29/40 (73{\%}) cases fulfilled at least two of the three Paris criteria. Applying the recently designed simplified IAIHG scoring system, 35/40 (88{\%}) had a {"}definite{"} diagnosis of AIH. This study supports the hypothesis that a complete response to corticosteroids may denote a variant of a PBC-AIH overlap syndrome which could be identified prior to treatment by modified Paris criteria in concert with the simplified IAIHG scoring system.",
keywords = "AIH, Autoimmune cholangitis, Autoimmune hepatitis, Corticosteroid therapy, IAIHG, Overlap syndromes, PBC",
author = "Qixia Wang and Carlo Selmi and Xinmin Zhou and Dekai Qiu and Zenshan Li and Qi Miao and Xiaoyu Chen and Jianhong Wang and Krawitt, {Edward L.} and Gershwin, {M. Eric} and Ying Han and Xiong Ma",
year = "2013",
month = "3",
doi = "10.1016/j.jaut.2012.10.004",
language = "English (US)",
volume = "41",
pages = "140--145",
journal = "Journal of Autoimmunity",
issn = "0896-8411",
publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - Epigenetic considerations and the clinical reevaluation of the overlap syndrome between primary biliary cirrhosis and autoimmune hepatitis

AU - Wang, Qixia

AU - Selmi, Carlo

AU - Zhou, Xinmin

AU - Qiu, Dekai

AU - Li, Zenshan

AU - Miao, Qi

AU - Chen, Xiaoyu

AU - Wang, Jianhong

AU - Krawitt, Edward L.

AU - Gershwin, M. Eric

AU - Han, Ying

AU - Ma, Xiong

PY - 2013/3

Y1 - 2013/3

N2 - Epigenetic changes are of crucial importance in the etiopathogenesis of autoimmune liver diseases. Among these, there is limited agreement on the definitions and treatment of primary biliary cirrhosis (PBC) and autoimmune hepatitis (AIH) overlap syndromes, we evaluated a large series of consecutive patients with PBC (n = 565) and AIH (n = 196) to identify a group of patients with corticosteroid-responsive PBC-AIH overlap syndrome. Within this series, a total of 490 patients were biopsied based upon staging or diagnostic needs. Review of the biopsies in conjunction with the International AIH Group criteria identified 80 patients with suspected overlap syndrome and 52 patients agreed to participate in the study and were prospectively treated with corticosteroids. Of these, 40/52 (77%) achieved a complete biochemical response (i.e. normal ALT, AST, and IgG) within 12 months of treatment. A survey of pre-treatment characteristics of the 40 responders revealed more severe interface hepatitis. Serum IgG levels ≥1.3x the upper limit of normal had 60% sensitivity and 97% specificity rates for steroid-responsiveness while the use of a higher threshold (≥2.0x) reduced sensitivity to 10%. When the Paris criteria for PBC-AIH were applied to the steroid-responsive patients, 29/40 (73%) cases fulfilled at least two of the three Paris criteria. Applying the recently designed simplified IAIHG scoring system, 35/40 (88%) had a "definite" diagnosis of AIH. This study supports the hypothesis that a complete response to corticosteroids may denote a variant of a PBC-AIH overlap syndrome which could be identified prior to treatment by modified Paris criteria in concert with the simplified IAIHG scoring system.

AB - Epigenetic changes are of crucial importance in the etiopathogenesis of autoimmune liver diseases. Among these, there is limited agreement on the definitions and treatment of primary biliary cirrhosis (PBC) and autoimmune hepatitis (AIH) overlap syndromes, we evaluated a large series of consecutive patients with PBC (n = 565) and AIH (n = 196) to identify a group of patients with corticosteroid-responsive PBC-AIH overlap syndrome. Within this series, a total of 490 patients were biopsied based upon staging or diagnostic needs. Review of the biopsies in conjunction with the International AIH Group criteria identified 80 patients with suspected overlap syndrome and 52 patients agreed to participate in the study and were prospectively treated with corticosteroids. Of these, 40/52 (77%) achieved a complete biochemical response (i.e. normal ALT, AST, and IgG) within 12 months of treatment. A survey of pre-treatment characteristics of the 40 responders revealed more severe interface hepatitis. Serum IgG levels ≥1.3x the upper limit of normal had 60% sensitivity and 97% specificity rates for steroid-responsiveness while the use of a higher threshold (≥2.0x) reduced sensitivity to 10%. When the Paris criteria for PBC-AIH were applied to the steroid-responsive patients, 29/40 (73%) cases fulfilled at least two of the three Paris criteria. Applying the recently designed simplified IAIHG scoring system, 35/40 (88%) had a "definite" diagnosis of AIH. This study supports the hypothesis that a complete response to corticosteroids may denote a variant of a PBC-AIH overlap syndrome which could be identified prior to treatment by modified Paris criteria in concert with the simplified IAIHG scoring system.

KW - AIH

KW - Autoimmune cholangitis

KW - Autoimmune hepatitis

KW - Corticosteroid therapy

KW - IAIHG

KW - Overlap syndromes

KW - PBC

UR - http://www.scopus.com/inward/record.url?scp=84875950918&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875950918&partnerID=8YFLogxK

U2 - 10.1016/j.jaut.2012.10.004

DO - 10.1016/j.jaut.2012.10.004

M3 - Article

VL - 41

SP - 140

EP - 145

JO - Journal of Autoimmunity

JF - Journal of Autoimmunity

SN - 0896-8411

ER -